Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

Michael J. Borowitz, MD, PhD, Brent L. Wood, MD, PhD, Meenakshi Devidas, PhD, Mignon L Loh, MD, Elizabeth A. Raetz, MD, Wanda Salzer, MD, James Nachman, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Cheryl L Willman, MD, Stephen B. Linda, MS, Naomi Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Eric C. Larsen, MD

Blood (2011) 118 (21): 1440.

https://doi.org/10.1182/blood.V118.21.1440.1440

Published: 2011

Journal Articles

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

Eric C. Larsen, MD, Wanda Salzer, MD, James Nachman, MD, Meenakshi Devidas, PhD, David R. Freyer, DO, MS, Elizabeth A. Raetz, MD, Naomi Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2011) 118 (21): 1510.

https://doi.org/10.1182/blood.V118.21.1510.1510

Published: 2011

Journal Articles

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Frank G Keller, MD, James Nachman, MD, Louis Constine, MD, John Thomson, MD, Kathleen M McCarten, MD, Lu Chen, PhD, Cindy Schwartz, MD

Blood (2010) 116 (21): 767.

https://doi.org/10.1182/blood.V116.21.767.767

Published: 2010

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Allotransplantation in pediatric HL

James Nachman

Blood (2009) 114 (10): 2008–2009.

https://doi.org/10.1182/blood-2009-07-228973

Published: 2009

Journal Articles

Apples and oranges: mixed lineage acute leukemia

James Nachman

Blood (2009) 113 (21): 5036.

https://doi.org/10.1182/blood-2009-02-203232

Published: 2009

Journal Articles

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock, Mei La, Ben Sanford, Clara D. Bloomfield, James W. Vardiman, Paul Gaynon, Richard A. Larson, James Nachman

Blood (2008) 112 (5): 1646–1654.

https://doi.org/10.1182/blood-2008-01-130237

Published: 2008

Journal Articles

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Yousif Matloub, MD, Anne Angiolillo, MD, Bruce Bostrom, MD, Stephen P. Hunger, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Naomi Winick, MD, Paul S. Gaynon, MD

Blood (2006) 108 (11): 146.

https://doi.org/10.1182/blood.V108.11.146.146

Published: 2006

Journal Articles

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Caroline Hastings, MD, Harland N. Sather, PhD, Nita L. Seibel, MD, James Nachman, MD, Peter G. Steinherz, MD, Kathy Bertolone, FNP, Cynthia DeLaat, MD, Lawrence J. Ettinger, MD, Janet Franklin, MD, David Robert Freyer, DO, Leonard A. Mattano, MD, Torrey L. Mitchell, MD, Charles M. Rubin, MD, Allan F. Pyesmany, MD, Nyla A. Heerema, PhD, Cheryl Edens, Paul S. Gaynon, MD

Blood (2006) 108 (11): 1870.

https://doi.org/10.1182/blood.V108.11.1870.1870

Published: 2006

Journal Articles

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Yousif Matloub, Susan Lindemulder, Paul S. Gaynon, Harland Sather, Mei La, Emmett Broxson, Rochelle Yanofsky, Raymond Hutchinson, Nyla A. Heerema, James Nachman, Marilyn Blake, Linda M. Wells, April D. Sorrell, Margaret Masterson, John F. Kelleher, Linda C. Stork

Blood (2006) 108 (4): 1165–1173.

https://doi.org/10.1182/blood-2005-12-011809

Published: 2006

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

Journal Articles

Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group

Fatih M. Uckun, Harland N. Sather, Paul S. Gaynon, Diane C. Arthur, Michael E. Trigg, David G. Tubergen, James Nachman, Peter G. Steinherz, Martha G. Sensel, Gregory H. Reaman

Blood (1997) 90 (1): 28–35.

https://doi.org/10.1182/blood.V90.1.28

Published: 1997

Journal Articles

Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Fatih M. Uckun, Zhiwen Yang, Harland Sather, Peter Steinherz, James Nachman, Bruce Bostrom, Lisa Crotty, Mireille Sarquis, Onur Ek, Tamer Zeren, David Tubergen, Gregory Reaman, Paul Gaynon

Blood (1997) 89 (10): 3769–3777.

https://doi.org/10.1182/blood.V89.10.3769

Published: 1997

Journal Articles

Clinical Features and Treatment Outcome of Children With Biphenotypic CD2 + CD19 + Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Fatih M. Uckun, Paul Gaynon, Harland Sather, Diane Arthur, Michael Trigg, David Tubergen, James Nachman, Peter Steinherz, Martha G. Sensel, Gregory R. Reaman

Blood (1997) 89 (7): 2488–2493.

https://doi.org/10.1182/blood.V89.7.2488

Published: 1997

NARROW

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Allotransplantation in pediatric HL

Apples and oranges: mixed lineage acute leukemia

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group

Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Clinical Features and Treatment Outcome of Children With Biphenotypic CD2 + CD19 + Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only